<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01856751</url>
  </required_header>
  <id_info>
    <org_study_id>TGA-TEM</org_study_id>
    <nct_id>NCT01856751</nct_id>
  </id_info>
  <brief_title>Use of a TGA and TEM in the Assessment of the Efficacy of Treatment With APCC or rFVIIa</brief_title>
  <acronym>Thrombus</acronym>
  <official_title>Use of a TGA and TEM in the Assessment of the Efficacy of Treatment With APCC or rFVIIa Concentrate in Patients With Acquired Haemophilia and in Patients With Haemophilia A With Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stowarzyszenie Pomocy Chorym na Zakrzepicę i Skazy Krwotoczne Thrombus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stowarzyszenie Pomocy Chorym na Zakrzepicę i Skazy Krwotoczne Thrombus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Occurrence of inhibitors to coagulation factor VIII is diagnosed in ~30% patients with
      haemophilia A. Presence of inhibitor with a titre &gt;5 BU/ml requires the use of by-passing
      agents: recombinant activated Factor VIIa concentrate (rFVIIa) and/or activated prothrombin
      complex concentrate (APCC). Similarly, haemorrhagic complications in patients with acquired
      haemophilia and inhibitor titre &gt;5 BU/ml should be treated with by-passing agents.

      Response to treatment with by-passing agents is patient-specific, and can vary in the same
      patient during subsequent bleedings. Some patients have good response to both products,
      however in other patients a better bleeding control is provided by one of the mentioned above
      agents (APCC or rFVIIa). There are clinical situations when severe bleedings requires an
      alternate use of both these agents.

      Traditional methods of laboratory tests used post-treatment in patients with haemophilia
      without inhibitors are useless in the presence of inhibitor. Laboratory monitoring of therapy
      with by-passing agents is possible with the use of global tests for the coagulation process
      assessment, which are as follows: thrombin generation assay (TGA) and thromboelastometry
      (TEM).

      Several studies revealed that TGA allows a monitoring of therapy with by-passing agents in
      patients with haemophilia A and inhibitor - the choice of the most effective treatment option
      - agent type and its dose, as well as laboratory assessment of treatment efficacy.

      Up to date, laboratory tests assessing the efficacy of by-passing agents in patients with
      acquired haemophilia were not conducted.

      In Factor VIII or IX deficiency conditions, fibrin's fibres generated by thrombin are
      morphologically thicker, and blood clots have increased susceptibility to fibrinolytic
      enzymes. Blood clot stability may be assessed with the use of thromboelastometry (TEM). We
      can hypothesize that simultaneous use of TGA and TEM methods may allow for an assessment of
      patient's individual response to therapy with by-passing agents. Clinical significance of the
      minimal dose of APCC and rFVIIa, needed to TGA and TEM normalization, requires further
      studies.

      Tests' purpose: Examination of the hypothesis that simultaneous use of thrombin generation
      assay (TGA) and thromboelastometry (TEM) may facilitate the choice of optimal therapy with
      by-passing agents and laboratory monitoring of efficacy of those agents in patients with
      acquired haemophilia or haemophilia A with inhibitor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This section is Not applicable
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of patient's individual response to therapy with by-passing agents by simultaneous use of TGA and TEM methods.</measure>
    <time_frame>48 hours</time_frame>
    <description>This is non-inverventional study as the protocol will not assign specific treatment to the particular subjects of the study. Patients will be treated with APCC or rFVIIa based on the experience of the study site. Patients are prescribed a treatment according to their physician's judgement or local clinical practice. This is observation of the everyday clinical practise on site.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Haemophilia</condition>
  <arm_group>
    <arm_group_label>haemophilia</arm_group_label>
    <description>Patients with acquired haemophilia. Patients with haemophilia A with inhibitor.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      this data is not applicable
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        60 patients with acquired haemophilia 20 patients with congenital haemophilia A with
        inhibitor
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with acquired haemophilia

          -  patients with congenital haemophilia A with inhibitor

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Krystyna Zawilska, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centrum Diagnostyczno - Lecznicze INTERLAB</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Podolak-Dawidziak, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Katedra i Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku, Akademia Medyczna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrzej Mital, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Katedra i Klinika Hematologii i Transplantologii Gdanski Uniwersytet Medyczny</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jerzy Windyga, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instytut Hematologii i Transfuzjologii w Warszawie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Krzysztof Chojnowski, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinika Hematologii Uniwersytetu Medycznego w Lodzi Wojewodzki Szpital Specjalistyczny im. M. Kopernika</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacek Musial, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Szpital Uniwersytecki w Krakowie, Oddzial Kliniczny Alergii i Immunologii</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Krystyna M Zawilska, MD, PhD</last_name>
    <phone>48618333949</phone>
    <email>k.zawilska@interia.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Katedra i Klinika Hematologii i Transplantologii Gdanski Uniwersytet Medyczny</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrzej Mital, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki w Krakowie, Oddzial Kliniczny Alergii i Immunologii</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacek Musial, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika Hematologii Uniwersytetu Medycznego w Lodzi Wojewodzki Szpital Specjalistyczny im. M. Kopernika</name>
      <address>
        <city>Lodz</city>
        <zip>93-510</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krzysztof Chojnowski, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Diagnostyczno - Lecznicze INTERLAB</name>
      <address>
        <city>Poznan</city>
        <zip>61-505</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krystyna Zawilska, MD,PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instytut Hematologii i Transfuzjologii w Warszawie</name>
      <address>
        <city>Warszawa</city>
        <zip>02-776</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerzy Windyga, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Katedra i Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku, Akademia Medyczna</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Podolak-Dawidziak, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Dargaud Y, Negrier C. Thrombin generation testing in haemophilia comprehensive care centres. Haemophilia. 2010 Mar;16(2):223-30. doi: 10.1111/j.1365-2516.2009.02082.x. Epub 2009 Aug 27. Review.</citation>
    <PMID>19719549</PMID>
  </reference>
  <reference>
    <citation>Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia. 2009 Jan;15(1):3-10. doi: 10.1111/j.1365-2516.2008.01931.x. Epub 2008 Nov 10. Review.</citation>
    <PMID>19016901</PMID>
  </reference>
  <reference>
    <citation>Dargaud Y, Bordet JC, Lienhart A, Negrier C. Use of the thrombin generation test to evaluate response to treatment with recombinant activated factor VII. Semin Hematol. 2008 Apr;45(2 Suppl 1):S72-3. doi: 10.1053/j.seminhematol.2008.03.008.</citation>
    <PMID>18544431</PMID>
  </reference>
  <reference>
    <citation>Livnat T, Martinowitz U, Zivelin A, Seligsohn U. Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma. Haemophilia. 2008 Jul;14(4):782-6. doi: 10.1111/j.1365-2516.2008.01688.x. Epub 2008 Mar 21.</citation>
    <PMID>18371162</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2013</study_first_submitted>
  <study_first_submitted_qc>May 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2013</study_first_posted>
  <last_update_submitted>December 17, 2015</last_update_submitted>
  <last_update_submitted_qc>December 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Haemophilia</keyword>
  <keyword>TGA</keyword>
  <keyword>TEM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

